JPH0337524B2 - - Google Patents

Info

Publication number
JPH0337524B2
JPH0337524B2 JP55046321A JP4632180A JPH0337524B2 JP H0337524 B2 JPH0337524 B2 JP H0337524B2 JP 55046321 A JP55046321 A JP 55046321A JP 4632180 A JP4632180 A JP 4632180A JP H0337524 B2 JPH0337524 B2 JP H0337524B2
Authority
JP
Japan
Prior art keywords
acid
solution
derivative
inflammatory
phospholipid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP55046321A
Other languages
English (en)
Japanese (ja)
Other versions
JPS55141407A (en
Inventor
Gitsuchi Mikurosu
Ritsutsuman Getsutsu
Erudesu Adorujan
Etsushenberuku Oigen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
A Natterman und Cie GmbH
Original Assignee
A Natterman und Cie GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by A Natterman und Cie GmbH filed Critical A Natterman und Cie GmbH
Publication of JPS55141407A publication Critical patent/JPS55141407A/ja
Publication of JPH0337524B2 publication Critical patent/JPH0337524B2/ja
Granted legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A61K47/544—Phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP4632180A 1979-04-11 1980-04-10 Nonoral administration solution containing arylacetic acid or arylpropionic acid derivative Granted JPS55141407A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19792914788 DE2914788A1 (de) 1979-04-11 1979-04-11 Parenteral applizierbare, stabile arzneimittelloesungen mit entzuendungshemmender wirkung

Publications (2)

Publication Number Publication Date
JPS55141407A JPS55141407A (en) 1980-11-05
JPH0337524B2 true JPH0337524B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1991-06-05

Family

ID=6068137

Family Applications (1)

Application Number Title Priority Date Filing Date
JP4632180A Granted JPS55141407A (en) 1979-04-11 1980-04-10 Nonoral administration solution containing arylacetic acid or arylpropionic acid derivative

Country Status (14)

Country Link
US (1) US4309421A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (1) JPS55141407A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AT (1) AT369651B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU539044B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BE (1) BE882731A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA1144480A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CH (1) CH642546A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DE (1) DE2914788A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
FR (1) FR2453644B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
GB (1) GB2046094B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IT (1) IT1148790B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NL (1) NL8002097A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SE (1) SE451427B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ZA (1) ZA802157B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3042365C2 (de) * 1980-11-10 1987-01-29 Extrakta Strauss GmbH, 2000 Hamburg Flüssige, lecithinhaltige einphasige Mehrstoffsysteme und Verfahren zu ihrer Herstellung
JPS57203011A (en) * 1981-06-05 1982-12-13 Taiyo Yakuhin Kogyo Kk Anti-inflammatory external agent
EP0146243A1 (en) * 1983-10-31 1985-06-26 Merck Frosst Canada Inc. Lipoxygenase inhibitors
DE3346526C2 (de) * 1983-12-22 1986-12-11 A. Nattermann & Cie GmbH, 5000 Köln Pharmazeutisches Präparat zur therapeutischen Behandlung von rheumatischen Erkrankungen
DE3346525C2 (de) * 1983-12-22 1987-03-19 A. Nattermann & Cie GmbH, 5000 Köln Pharmazeutische Zubereitung mit speziellen 1,2-Diacyl-glycero-3-phosphocholinen zur Behandlung von Erkrankungen im Magen-Darmbereich
JPH0647533B2 (ja) * 1984-08-10 1994-06-22 裕 水島 ４−ビフエニリル酢酸系化合物含有脂肪乳剤
US5171566A (en) * 1986-05-16 1992-12-15 The Green Cross Corporation Flurbiprofen derivative ophthalmic preparation
DE3621036A1 (de) * 1986-06-24 1988-01-07 Merckle Gmbh Fluessige ibuprofen-zubereitungen
US4877619A (en) * 1986-08-25 1989-10-31 Vestar, Inc. Liposomal vesicles for intraperitoneal administration of therapeutic agents
CH673395A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) * 1987-01-30 1990-03-15 Ciba Geigy Ag
US5283067A (en) * 1987-01-30 1994-02-01 Ciba-Geigy Corporation Parenteral suspensions
CA1319886C (en) * 1987-02-03 1993-07-06 Alberto Ferro Mixed micelle solutions
US4960799A (en) * 1988-09-13 1990-10-02 Ciba-Geigy Corporation Stabilized aqueous solutions of pharmaceutically acceptable salts of ortho-(2,6-dichlorophenyl)-aminophenylacetic acid for opthalmic use
IT1242642B (it) * 1990-04-17 1994-05-16 Alfa Wassermann Spa Formulazioni iniettabili contenenti naproxen sale sodico.
US5091187A (en) * 1990-04-26 1992-02-25 Haynes Duncan H Phospholipid-coated microcrystals: injectable formulations of water-insoluble drugs
US5091188A (en) * 1990-04-26 1992-02-25 Haynes Duncan H Phospholipid-coated microcrystals: injectable formulations of water-insoluble drugs
US5246707A (en) * 1990-04-26 1993-09-21 Haynes Duncan H Sustained release delivery of water-soluble bio-molecules and drugs using phospholipid-coated microcrystals, microdroplets and high-concentration liposomes
DE4124252A1 (de) * 1991-07-22 1993-01-28 Knoll Ag Verfahren zur herstellung einer sterilfiltrierbaren wirkstoffloesung
US5389681A (en) * 1992-10-22 1995-02-14 Ciba-Geigy Corporation Parenteral solutions for diclofenac salts
DE4305003A1 (de) * 1993-02-18 1994-08-25 Knoll Ag Verfahren zur Herstellung kolloidaler wäßriger Lösungen schwer löslicher Wirkstoffe
EP1214940B1 (en) * 1995-01-27 2009-03-11 Board of Regents, The University of Texas System Methods of enhancing the therapeutic activity of NSAIDs and compositions of zwitterionic phospholipids useful therein
US5763422A (en) * 1995-01-27 1998-06-09 Board Of Regents, The University Of Texas System Methods of enhancing the therapeutic activity of NSAIDS and compositions of zwitterionic phospholipids useful therein
DE69637441T2 (de) 1995-10-17 2009-03-05 Jagotec Ag Verabreichung unlöslicher arzneistoffe
US7255877B2 (en) 1996-08-22 2007-08-14 Jagotec Ag Fenofibrate microparticles
US6465016B2 (en) 1996-08-22 2002-10-15 Research Triangle Pharmaceuticals Cyclosporiine particles
GB9625589D0 (en) * 1996-12-10 1997-01-29 Boots Co Plc Therapeutic agents
ES2201673T3 (es) * 1998-02-11 2004-03-16 Rtp Pharma Corporation Combinacion de esteroides y acidos grasos poiinsaturados para el tratamiento de estados inflamatorios.
US6979456B1 (en) 1998-04-01 2005-12-27 Jagotec Ag Anticancer compositions
CA2333648C (en) 1998-05-29 2008-10-21 Rtp Pharma Inc. Thermoprotected microparticle compositions and process for terminal steam sterilization thereof
US6153225A (en) * 1998-08-13 2000-11-28 Elan Pharma International Limited Injectable formulations of nanoparticulate naproxen
AU759641B2 (en) 1998-08-19 2003-04-17 Skyepharma Canada Inc. Injectable aqueous dispersions of propofol
US6180136B1 (en) * 1998-11-10 2001-01-30 Idexx Laboratories, Inc. Phospholipid-coated microcrystals for the sustained release of pharmacologically active compounds and methods of their manufacture and use
IL143197A0 (en) 1998-11-20 2002-04-21 Rtp Pharma Inc Dispersible phospholipid stabilized microparticles
EP1214059B1 (en) * 1999-09-21 2005-05-25 Skyepharma Canada Inc. Surface modified particulate compositions of biologically active substances
EP1276465B1 (en) 2000-04-20 2014-03-12 Jagotec AG Improved water-insoluble drug particle process
US6429223B1 (en) * 2000-06-23 2002-08-06 Medinox, Inc. Modified forms of pharmacologically active agents and uses therefor
US6634576B2 (en) 2000-08-31 2003-10-21 Rtp Pharma Inc. Milled particles
AU2001255515A1 (en) * 2000-09-20 2002-04-02 Skyepharma Canada Inc. Stabilised fibrate microparticles
US8586094B2 (en) 2000-09-20 2013-11-19 Jagotec Ag Coated tablets
WO2002067901A1 (en) * 2001-02-22 2002-09-06 Skyepharma Canada Inc. Fibrate-statin combinations with reduced fed-fasted effects
US20040132823A1 (en) * 2001-11-02 2004-07-08 Leo Pavliv Pharmaceutical composition of 2-(4-isobutylphenyl) propionic acid
CA2534241C (en) * 2003-07-31 2012-05-29 The Board Of Regents Of The University Of Texas System Compositions and methods for treating, preventing and/or ameliorating cancers, the onset of cancers or the symptoms of cancers
WO2007142707A1 (en) * 2006-02-06 2007-12-13 Pharmaceutical Solutions, Inc. Non-steroidal anti-inflammatory oral powder and liquid preparations for administration to animals
WO2008013822A2 (en) * 2006-07-26 2008-01-31 The Board Of Regent Of The University Of Texas System Parenteral preparations of gi-safer phospholipid-associated anti-inflammatories and methods of preparation and use
CN102413687A (zh) 2009-03-12 2012-04-11 坎伯兰医药品股份有限公司 静脉注射布洛芬的施用
US8871810B2 (en) 2009-07-15 2014-10-28 Cumberland Pharmaceuticals Inc. Treating critically ill patients with intravenous ibuprofen
US8735452B2 (en) * 2009-07-15 2014-05-27 Cumberland Pharmaceuticals Inc. Treating patients with intravenous ibuprofen
CA2766367A1 (en) * 2009-07-31 2011-02-03 Cumberland Pharmaceuticals Inc. Treating critically ill patients with intravenous ibuprofen
FR2971712B1 (fr) * 2011-02-22 2016-06-10 Map France Solution stable de ketoprofene pour injection intraveineuse
US9072710B2 (en) 2012-03-16 2015-07-07 Cumberland Pharmaceuticals Inc. Injectable ibuprofen formulation
US9072661B2 (en) 2012-03-16 2015-07-07 Cumberland Pharmaceuticals Inc. Injectable ibuprofen formulation
AU2013232038B2 (en) 2012-03-16 2016-07-07 Cumberland Pharmaceuticals, Inc. Injectable ibuprofen formulation
US9321749B1 (en) 2012-07-25 2016-04-26 Globavir Biosciences, Inc. Heterocyclic compounds and uses thereof
JP6154025B2 (ja) 2012-12-24 2017-06-28 ニューロガストルクス，インコーポレイテッド Ｇｉ管障害を治療するための方法
US20140275261A1 (en) 2013-03-15 2014-09-18 Dr. Reddy's Laboratories, Inc. Diclofenac parenteral compositions
US9844554B2 (en) 2014-06-24 2017-12-19 Neurogastrx, Inc. Prodrugs of metopimazine
US10836757B1 (en) 2020-04-02 2020-11-17 Neurogastrx, Inc. Polymorphic forms of metopimazine

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3044931A (en) * 1960-01-27 1962-07-17 Geigy Chem Corp Aryloxy acetic acid amides: process for parenteral application
CA725596A (en) * 1960-08-26 1966-01-11 J. Wretlind Arvid Method of preparing intravenously injectable fat emulsions free from side reactions or complications
JPS5186117A (en) * 1975-01-27 1976-07-28 Tanabe Seiyaku Co Johoseibiryushiseizainoseiho
GB1523965A (en) * 1976-03-19 1978-09-06 Ici Ltd Pharmaceutical compositions containing steroids
IT1202370B (it) * 1976-07-12 1989-02-09 Hoffmann La Roche Soluzioni inietabili in cui l'atti vita' emolitica degli agenti di formazione di micelle naturali e' evitata mediante l'aggiunta di lipoidi e relativi prodotti
GB1575343A (en) * 1977-05-10 1980-09-17 Ici Ltd Method for preparing liposome compositions containing biologically active compounds
DE2856333C2 (de) * 1978-12-27 1983-09-22 A. Nattermann & Cie GmbH, 5000 Köln Oral einnehmbare Arzneimittel mit entzündungshemmender Wirkung
JPS6320209A (ja) * 1986-07-11 1988-01-27 Mitsubishi Motors Corp 油圧サスペンシヨン装置を備える車両の車高調整方法

Also Published As

Publication number Publication date
AU539044B2 (en) 1984-09-06
ATA195880A (de) 1982-06-15
IT1148790B (it) 1986-12-03
BE882731A (fr) 1980-07-31
US4309421A (en) 1982-01-05
JPS55141407A (en) 1980-11-05
IT8021299A0 (it) 1980-04-10
CH642546A5 (de) 1984-04-30
CA1144480A (en) 1983-04-12
SE8002714L (sv) 1980-10-12
NL8002097A (nl) 1980-10-14
ZA802157B (en) 1981-05-27
FR2453644A1 (fr) 1980-11-07
DE2914788A1 (de) 1980-10-16
SE451427B (sv) 1987-10-12
AT369651B (de) 1983-01-25
GB2046094B (en) 1983-10-26
FR2453644B1 (fr) 1985-07-05
AU5733180A (en) 1980-10-16
GB2046094A (en) 1980-11-12
DE2914788C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1990-06-21

Similar Documents

Publication Publication Date Title
JPH0337524B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA1133395A (en) Inflammation-preventing pharmaceutical composition of oral administration
JP3027103B2 (ja) アルガトロバンの高濃度水溶液
US4369182A (en) Inflammation-preventing pharmaceutical composition of oral administration
KR100884493B1 (ko) 위장관을 보호하고 개선된 치료학적 활성을 제공하기위한, 레시틴 오일과 ｎｓａｉｄ의 제형을 사용하는 방법및 조성물
JPH0437801B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JPH0534334B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP2065047A1 (en) Methods of enhancing the therapeutic activity of NSAIDS and compositions of zwitterionic phospholipids useful therein
US4309420A (en) Stable injectable solutions of indoleacetic acid derivatives
CA2657769C (en) Preparations of phospholipids and pharmaceuticals containing 5-amino salicylic acid for the treatment of inflammatory bowel disease
JPH0577653B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP1214940B1 (en) Methods of enhancing the therapeutic activity of NSAIDs and compositions of zwitterionic phospholipids useful therein
IL173330A (en) Sterilized by a filter for relief of inflammation, pain or fever and a method of preparing it
JP4519640B2 (ja) 非ペプチドレニン阻害薬及び界面活性剤を含有する医薬製剤
JPS63192716A (ja) 非経口投与用懸濁液
JPH02250876A (ja) ２―フェニル―１，２―ベンズイソセレナゾール―３（２ｈ）―オンの安定した非経口溶液及びその製造方法
JP2928261B2 (ja) 安定なポリプレニル系化合物含有組成物の製法
JPH03106821A (ja) 抗腫瘍剤
JPH10505818A (ja) リポソーム製剤
BRPI0613671A2 (pt) complexo de associação intermolecular de um transportador e de um princìpio ativo